循环时钟基因:它们对肝脏新陈代谢,疾病发展和治疗的影响 (综述)
Junmin Wang1, Mengxing Cao1, Shen Li2
1Department of Gastroenterology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071, P.R. China.
Molecular medicine reports
|October 17, 2025
概括
循环时钟基因显著影响肝脏新陈代谢和疾病进展. 破坏这些节奏有助于肝脏疾病,但慢性疗法提供了有前途的治疗策略.
科学领域:
- 肝病学和时间生物学
- 分子医学是分子医学.
背景情况:
- 昼夜节律是影响新陈代谢,免疫和内分泌功能的核心调节系统,通过中央外周网络.
- 昼夜节律的破坏与各种肝脏疾病的发病有关,包括NAFLD,ALD,纤维化和HCC.
研究的目的:
- 综合审查昼夜钟基因在肝脏代谢和肝脏疾病中的作用.
- 探索慢性治疗策略在肝病治疗中的潜力.
主要方法:
- 关于昼夜钟基因和肝脏疾病的基础研究和临床证据的审查.
- 分析关键的昼夜调节器及其对肝脏代谢和炎症通路的影响.
主要成果:
- 关键的昼夜调节器 (例如,CLOCK,BMAL1,PER,CRY) 调节脂肪/葡萄糖代谢和胆酸合成等关键途径.
- 循环节的干扰会通过改变代谢和炎症反应加剧肝病的进展.
- 长期治疗方法 (药物学,时间限制的养,光疗) 显示出临床前景.
结论:
- 循环时钟基因对于调节肝脏新陈代谢和影响肝病进展至关重要.
- 时间疗法在肝病学中为精准医学提供了潜在的途径.
- 需要进一步的研究来阐明机制,并促进临床应用基于昼夜治疗的疗法.
相关概念视频
Circadian Rhythms and Gene Regulation
4.5K
The biological clock is involved in many aspects of regulating complex physiology in all animals. It was in 1935 when German zoologists, Hans Kalmus and Erwin Bünning, discovered the existence of circadian rhythm in Drosophila melanogaster. However, the internal molecular mechanisms behind the circadian clock remained a mystery until 1984, when Jeffrey C. Hall, Michael Rosbash, and Michael W. Young discovered the expression of the Per gene oscillating over a 24-hour cycle. In subsequent...
4.5K
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
350
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
350
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
211
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
211
Factors Affecting Drug Biotransformation: Biological
516
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
516
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
180
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
180
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
249
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
249


